EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Treatment Decisions in Multiple Myeloma

Tarek H Mouhieddine iD, Kenneth C Anderson

New England Journal of Medicine · 10.09.2026 · 395 (10) · 992-1008

DOI: 10.1056/nejmra2605253 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift New England Journal of Medicine, erschienen am 10.09.2026. Verfasst von Tarek H Mouhieddine und 1 weiteren Autor:innen. Beteiligte Einrichtung: Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Clinical Decision-Making, Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 124 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Revolutions in transplantation and targeted and immune therapies have transformed multiple myeloma from a disease with an associated survival of a few years into one for which functional cure is an emerging goal. This abundance of effective therapies has created clinical complexity. Here we provide a practical framework, anchored in trial evidence and informed by emerging biologic discoveries, for the navigation of treatment decisions across the disease spectrum. We outline how cytogenetic and genomic risk stratification, functional fitness, and measurable residual disease status individualize therapy in newly diagnosed disease, in which quadruplet induction therapy is now standard and the role of autologous transplantation is being reevaluated. Regarding relapse, we address the sequencing of B-cell maturation antigen-directed chimeric antigen receptor (CAR) T cells, bispecific antibodies, and antibody-drug conjugates, emphasizing T-cell fitness and multiantigen targeting to counter exhaustion and antigen escape. We also consider early interception in high-risk smoldering myeloma. Throughout, we underscore that enrollment of patients in clinical trials should be considered in order to ensure continued progress.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Decision-MakingMultiple MyelomaHumansNeoplasm, ResidualRecurrenceCytogenetic AnalysisRisk AssessmentImmunotherapy, AdoptiveReceptors, Chimeric AntigenNeoplasm Recurrence, LocalAntibodies, BispecificImmunoconjugatesAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsStem Cell TransplantationTransplantation, AutologousClinical Trials as Topic

Substanzen

Receptors, Chimeric AntigenAntibodies, BispecificImmunoconjugatesAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston.

ORCID-Profile: Tarek H Mouhieddine

Zitieren

APA

Mouhieddine, T. H., & Anderson, K. C. (2026). Treatment Decisions in Multiple Myeloma. New England Journal of Medicine, 395(10), 992-1008. https://doi.org/10.1056/nejmra2605253

Vancouver

Mouhieddine TH, Anderson KC. Treatment Decisions in Multiple Myeloma. New England Journal of Medicine. 2026;395(10):992-1008. doi:10.1056/nejmra2605253

BibTeX
@article{Mouhieddine2026,
  author = {Mouhieddine, Tarek H and Anderson, Kenneth C},
  title = {Treatment Decisions in Multiple Myeloma},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {10},
  pages = {992--1008},
  doi = {10.1056/nejmra2605253}
}
Kostenlos starten →